UNRESECTABLE MYXOID LIPOSARCOMA

Clinical trials for UNRESECTABLE MYXOID LIPOSARCOMA explained in plain language.

Never miss a new study

Get alerted when new UNRESECTABLE MYXOID LIPOSARCOMA trials appear

Sign up with your email to follow new studies for UNRESECTABLE MYXOID LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New immunotherapy targets rare cancers by harnessing the Body's immune system

Disease control Not yet recruiting

This phase 2 trial tests a new drug called brenetafusp (IMC-F106C) in people with rare cancers—synovial sarcoma and myxoid liposarcoma—that have spread or cannot be surgically removed. The drug is a type of immunotherapy designed to guide the body's immune cells to attack cancer …

Matched conditions: UNRESECTABLE MYXOID LIPOSARCOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jul 09, 2026 00:00 UTC

UNRESECTABLE MYXOID LIPOSARCOMA

Get alerted when new UNRESECTABLE MYXOID LIPOSARCOMA trials appear

New immunotherapy targets rare cancers by harnessing the Body's immune system